Deidre Coffey
Family · South Bend, INNPI 1467747014
Payments from drug & device makers
Across 153 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$398
- Lilly USA, LLC$284
- Novo Nordisk$192
- Boehringer Ingelheim$186
- AstraZeneca$168
- GSK$164
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,644100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $398 |
| Lilly USA, LLC | 20 | $284 |
| Novo Nordisk | 11 | $192 |
| Boehringer Ingelheim | 10 | $186 |
| AstraZeneca | 9 | $168 |
| GSK | 10 | $164 |
| Pfizer | 10 | $155 |
| Bayer | 8 | $138 |
| Exact Sciences | 7 | $103 |
| Amgen | 5 | $76 |
| Corium, LLC | 5 | $75 |
| Abbott | 4 | $74 |
| Novartis | 4 | $73 |
| Astellas Pharma US Inc | 4 | $72 |
| Dexcom, Inc. | 4 | $68 |
| Lundbeck LLC | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Viatris Specialty LLC | 2 | $39 |
| Mylan Specialty L.p. | 1 | $33 |
| Merck | 2 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
How this compares
$2,644 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 73 | $83,643 |
| OzempicSemaglutide | 49 | $70,787 |
| JardianceEmpagliflozin | 29 | $46,332 |
| MounjaroTirzepatide | 21 | $36,225 |
| EliquisApixaban | 28 | $34,915 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $24,070 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $24,042 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $22,813 |
| JanuviaSitagliptin Phosphate | 11 | $18,556 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $15,744 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $10,470 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $9,086 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $8,326 |
| AdderallDextroamphetamine/Amphetamine | 12 | $7,398 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $6,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $284 | $119,86894 claims |
| Novo NordiskOzempic | $192 | $70,78749 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $164 | $59,25582 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $186 | $56,80243 claims |
| PfizerEliquis | $155 | $34,91528 claims |
| MerckJanuvia | $31 | $18,55611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Adderall | $46 | $7,39812 claims |
| AstraZenecaSymbicort | $168 | $3,56016 claims |
| AbbVieSynthroid | $398 | $1,31531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.
Other family in South Bend
- Caitlin VlaeminckSouth Bend$14K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.